• Opinion
• [Desktop] Increase accessibility by beating generic prices
• by Kim, Jung-Ju Oct 19, 2022 05:48am

• Company
• Forxiga & Jardiance are expected to surpass 100 billion won
• by Nho, Byung Chul Oct 19, 2022 05:48am

• Policy
• Is it possible to benefit from the K-CAB 4th indication?
• by Lee, Tak-Sun Oct 17, 2022 10:52pm

• Opinion
• [Reporter’s View] The key to the ‘PE Exemption’ issue
• by Eo, Yun-Ho Oct 17, 2022 10:52pm

• Policy
• PVA, financial resources to register new drugs, not penaltie
• by Lee, Jeong-Hwan Oct 17, 2022 10:52pm

• Policy
• “No considerations made to protect generics” at NA audit
• by Lee, Jeong-Hwan Oct 17, 2022 10:52pm

• Company
• Shingrix costs 600,000 won
• by Kim, Jin-Gu Oct 17, 2022 10:51pm

• Shingrix, a shingles vaccine, will be released in December
• by Oct 17, 2022 06:03am

• InterView
• “AstraZeneca’s sincerity in oncology drives cont. growth"
• by Eo, Yun-Ho Oct 17, 2022 06:03am

• Policy
• 780,000 doses of Comirnaty 2 will be national lot released
• by Lee, Hye-Kyung Oct 17, 2022 06:03am